Cara Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Good morning. This is David Amsellem from the Piper Sandler specialty pharma team, day three of the Piper Sandler Healthcare Conference, or I should say 34th Annual Piper Sandler Healthcare Conference. And we're delighted to have Cara Therapeutics with us, Chris Posner, CEO; Joana Goncalves, Chief Medical Officer, did I get your title, right?
I do, okay. And Ryan Maynard, CFO. So thanks everyone for joining us. So lots to talk about given the commercialization of KORSUVA. So I thought we would just dive right in, if that's okay.
Sure, David.
Questions & Answers
So let's just start for those in the audience and on the webcast who may not be as aware of the underlying addressable population. Can you just give us a brief refresher of the underlying population for chronic kidney disease associated pruritus, particularly in the dialysis setting? And how do you see
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |